Improvement of inflammatory bowel diseases based on expression and functional changes of P-glycoprotein by methylpredonislone and essential fatty acids
Project/Area Number |
21590182
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Medical pharmacy
|
Research Institution | Tokyo University of Pharmacy and Life Science |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
TOMITA Mikio 東京薬科大学, 薬学部, 准教授 (60207610)
|
Project Period (FY) |
2009 – 2011
|
Project Status |
Completed (Fiscal Year 2011)
|
Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2011: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2010: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2009: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
Keywords | 炎症性腸疾患 / methylpredonisolone / P-glycoprotein / 薬物療法 / 栄養療法 / 必須不飽和脂肪 / Dextran Sodium Sulfate / P-glycoproein / 必須不飽和脂肪酸 / Dextran sodium sulfate / Methylprednisolone |
Research Abstract |
Linoleic acid(LA) and.-linolenic acid(α-LnA) decrease the absorption of methylpredonisolone(MP) from small intestine in inflammatory bowel disease(IBD) model rats and have delivery effects to large intestine to MP. LA and α-LnA have anti-inflammatory effects and regulatory effects on expression and function of P-glycoprotein(P-gp) in intestinal epithelial cells. It suggests that administration of these essential unsaturated fatty acids not only prevent progress of IBD and also normalize intestinal absorption and disposition of the drug which is a substrate of P-gp in vivo. More experimental information and data are necessary for more efficient administration schedule of drugs in IBD therapy.
|
Report
(4 results)
Research Products
(15 results)